Prevention and treatment of ovarian hyperstimulation syndrome

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 17, Issue 2, 2003, Pages 249-261

  Al Shawaf, Talha ^a   Grudzinskas, J G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Coasting; Controlled ovarian stimulation; Ovarian hyperstimulation syndrome; Withholding gonadotrophins

Indexed keywords

ALBUMIN; ANGIOTENSIN ANTAGONIST; ANTIHISTAMINIC AGENT; BUSERELIN; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN RECEPTOR; CORTICOSTEROID DERIVATIVE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN; HEPARIN; HETASTARCH; HISTAMINE; IMMUNOGLOBULIN; INDOMETACIN; LOW MOLECULAR WEIGHT HEPARIN; LUTEINIZING HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN INHIBITOR; SEX HORMONE; TRIPTORELIN; UNINDEXED DRUG; VASCULOTROPIN;

ASCITES FLUID; ASPIRATION; BLOOD VOLUME; BOLUS INJECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIURESIS; DOWN REGULATION; DRUG ANTAGONISM; DRUG COST; DRUG EFFICACY; EXTRAVASCULAR SPACE; FEMALE; FLUID BALANCE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; INJECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LAPAROSCOPY; LAPAROTOMY; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; OVARY DISEASE; OVARY FOLLICLE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK; SIDE EFFECT; SYMPTOM; THROMBOEMBOLISM; ULTRASOUND; WELLBEING;

EID: 0037765927     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6934(02)00127-X     Document Type: Review

References (65)

1. Mathur R & Jenkins J. Ovarian hyperstimulation syndrome: An endocrinopathy? Current Opinion in Obstetrics and Gynaecology 2001; 13: 329-333.
2. Whelan JG & Vlahos NE. The ovarian hyperstimulation syndrome. Fertility and Sterility 2000; 73: 883-896.
3. Mathur RS, Akande AV, Keay SD et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertility and Sterility 2000; 73: 901-907.
4. Blankstein J, Shalev J, Saadon T et al. Ovarian hyperstimulation syndrome: Prediction by number and size of preovulatory ovarian follicles. Fertility and Sterility 1987; 47: 597-602.
5. Enskog A, Henriksson M, Unander M et al. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility 1999; 71: 808-814.
6. Dahl Lyons CA, Wheeler CA, Fishman GN et al. Early and late presentation of the ovarian hyperstimulation syndrome: Two distinct entities with different risk factors. Human Reproduction 1994; 9: 792-799.
7. Soliman S, Daya S, Collins J & Hughes EG. The role of luteal phase support in infertility treatment: A meta-analysis of randomized trials. Fertility and Sterility 1994; 61: 1068-1076.
8. MacDougall MJ, Tan SL & Jacobs HS. In-vitro fertilization and the ovarian hyperstimulation syndrome. Human Reproduction 1992; 7: 597-600.
9. Al-Shawaf T, Zosmer A, Hussain S et al. Prevention of ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: A modified coasting strategy based on ultrasound for identification of high-risk patients. Human Reproduction 2001; 16: 24-30.
10. Felberbaum RE, Albano C, Ludwig M et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: A prospective uncontrolled phase III study. Human Reproduction 2000; 15: 1015-1020.
11. Al-Inany H & Aboulghar M. GnRH antagonist in assisted reproduction: A Cochrane review. Human Reproduction 2002; 17: 874-885.
12. Asch RH, Li H, Balmaceda JP et al. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: Definition of high risk groups. Human Reproduction 1991; 6: 1395-1399.
13. Delvigne A, Demoulin A, Smitz J et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: A Belgian multicentric study I. Clinical and biological features. Human Reproduction 1993; 8: 1353-1360.
14. Asch RH, Ivery G, Goldsman M et al. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Human Reproduction 1993; 8: 1015-1020.
15. Sher G, Zouves C, Feinman M & Massarani G. Prolonged coasting: An effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Human Reproduction 1995; 10: 3107-3109.
16. Benadiva CA, Davis O, Kligman I et al. Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertility and Sterility 1997; 67: 724-727.
17. McClure N, Healy DL, Roger PAW et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994; 344: 235-236.
18. Delvigne A & Rozenberg S. Preventive attitude of physicians to avoid OHSS in IVF patients. Human Reproduction 2001; 16: 2491-2495.
19. Waldenström U, Kahn J, Mark L & Nilsson S. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by prolonged coasting of very hyperstimulated patients: A multicentre study. Human Reproduction 1999; 14: 294-297.
20. Dhont M, Van Der Straeten F & De Sutter P. Prevention of severe ovarian hyperstimulation by coasting. Fertility and Sterility 1998; 70: 847-850.
21. Fluker MR, Hooper WM & Yuzpe AA. Withholding gonadotrophin (coasting) to minimize the risk of ovarian hyperstimulation during super ovulation and in vitro fertilization-embryo transfer cycles. Fertility and Sterility 1999; 71: 294-301.
22. Egbase PE, Al Sharhan M & Grudzinskas JG. Early coasting in patients with polycystic ovarian syndrome is consistent with good clinical outcome. Human Reproduction 2002; 17: 1212-1216.
23. Al-Shawaf T, Zosmer A, Tozer A et al. Value of measuring serum FSH in addition to serum estradiol in a coasting programme to prevent severe OHSS. Human Reproduction 2002; 17: 1117-1121.
24. Forman RG, Frydman R, Egan D et al. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: A European series and a proposal for prevention. Fertility and Sterility 1990; 53: 502-509.
25. Imoedemhe DA, Sigue AB, Pacpaco EL & Olazo AB. Stimulation of endogenous surge of lutinizing hormone with gonadotrophin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertility and Sterility 1991; 55: 328-332.
26. Lewit N, Kol S, Manor D & Itskovitz-Eldor J. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the introduction of ovulation and prevention of ovarian hyperstimulation syndrome: A case-control study. Human Reproduction 1996; 11: 1399-1402.
27. Trounson A, Wood C & Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertility and Sterility 1994; 62: 353-362.
28. Jaroudi K, Hollanders J, Elnour A et al. Embryo development and pregnancies from in-vitro matured and fertilized human oocytes. Human Reproduction 1999; 14: 1749-1751.
29. Amso NN, Ahuja KK, Moris N & Shaw RW. The management of predicted ovarian hyperstimulation involving gonadotrophin-releasing hormone analogue with elective cryopreservation of all pre-embryos. Fertility and Sterility 1990; 53: 1087-1090.
30. Salat-Baroux J, Alvvarez S, Antoine JM et al. Treatment of hyperstimulation during in-vitro fertilisation. Human Reproduction 1990; 5: 36-39.
31. Shaker AG, Zosmer A, Dean N et al. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertility and Sterility 1996; 65: 992-996.
32. Queenan JT Jr., Veek LL, Toner JP et al. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Human Reproduction 1997; 12: 1573-1576.
33. Shoham Z, Weissman A, Barash A et al. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: A prospective, randomized, placebo-controlled study. Fertility and Sterility 1994; 62: 137-142.
34. Lewit N, Kol S, Ronen N & Itskovitz-Eldor J. Does intravenous albumin administration of human albumin prevent severe ovarian hyperstimulation syndrome? Fertility and Sterility 1996; 66: 654-656.
35. Mukherjee T, Cooperman AB, Sandler B et al. Severe ovarian hyperstimulation syndrome despite prophylactic albumin at the time of oocyte retrieval for in vitro fertilisation and embryo transfer. Fertility and Sterility 1995; 64: 641-643.
36. Ng E, Leader A, Claman P et al. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. Human Reproduction 1995; 10: 807-810.
37. Ndukwe G, Thornton S, Fishel S et al. Severe ovarian hyperstimulation syndrome: Is it really preventable by prophylactic intravenous albumin? Fertility and Sterility 1997; 68: 851-854.
38. Aboulghar M, Evers JH, & Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews 2000; 2: CD001302.
39. Tan SL, Balen A, Hussein EL et al. The use of glucocorticoids for the prevention of ovarian hyperstimulation in IVF. Fertility and Sterility 1992; 58: 378-383.
40. Abe Y, Horiuchi A, Miyake M & Kimura S. Anti-cytokine nature of natural human immunoglobulin: One possible mechanism clinical effect of intravenous immunoglobulin therapy. Immunology Reviews 1994; 139: 5-19.
41. Orvieto R & Ben-Rafael Z. The immune system in severe ovarian hyperstimulation syndrome. Journal of Assisted Reproduction and Genetics 1997; 14: 79S.
42. Abramov Y, Fatum M, Abrahamov D & Schenker JG. Hydroxyethyl starch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: A preliminary report. Fertility and Sterility 2001; 75: 1828-1830.
43. Borenstein R, Elhalah U, Lenenfeld B & Schwariz Z. Severe ovarian hyperstimulation syndrome: A re-evaluated therapeutic approach. Fertility and Sterility 1989; 51: 791-795.
44. Brinsden P, Wada I, Tan S et al. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. British Journal of Obstetrics and Gynaecology 1995; 102: 767-772.
45. Navot D, Bergh PA & Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertility and Sterility 1992; 58: 249-261.
46. Dhabhar FS, Miller AH, McEwan BS & Spencer RL. Stress-induced changes in blood leukocyte distribution. Journal of Immunology 1996; 157: 1638-1644.
47. Ferraretti AP, Gianaroli L, Diotallevi L et al. Dopamine treatment for severe hyperstimulation syndrome. Human Reproduction 1992; 7: 180-183.
48. Balasch J, Fabregues F & Arroyo V. Peripheral arterial vasodilation hypothesis: A new insight into the pathogenesis of ovarian hyperstimulation syndrome. Human Reproduction 1998; 13: 2718-2730.
49. Balasch J, Arroyo V, Fabregues F et al. Neurohormonal and hemodynamic changes in severe cases of the ovarian hyperstimulation syndrome. Annals of Internal Medicine 1994; 121: 27-33.
50. Pride S, Yuen B, Moon Y & Leung P. Relationship of gonadotropin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. American Journal of Obstetrics and Gynecology 1986; 154: 1155-1160.
51. Anonymous. Management and prevention of ovarian hyperstimulation syndrome (OHSS). RCOG Guideline No. 5. London: RCOG; 1995.
52. Thaler I, Yoffe N, Kaftory J & Brandes J. Treatment of ovarian hyperstimulation syndrome: The physiological basis for a modified approach. Fertility and Sterility 1981; 36: 110-113.
53. Knox G. Antihistamine blockade of the ovarian hyperstimulation syndrome. American Journal of Obstetrics and Gynecology 1974; 118: 992-994.
54. Pride S, Yuen BH & Moon Y. Clinical, endocrinologic, and intraovarian prostaglandin F responses to H-1 receptor blockade in the ovarian hyperstimulation syndrome: Studies in the rabbit model. American Journal of Obstetrics and Gynecology 1984; 148: 670-674.
55. Erlik Y, Navot Y & Friedman M. Histamine levels in ovarian hyperstimulation syndrome. Obstetrics and Gynaecology 1979; 53: 580-582.
56. Zaidise I, Friedman M, Lindenbaum ES, et al. Serotonin and the ovarian hyperstimulation syndrome. European Journal of Obstetrical and Gynaecological Reproductive Biology 1983; 15: 55-60.
57. Aboulghar MA, Mansour RT, Serour GI et al. Autotransfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome. Fertility and Sterility 1992; 58: 1056-1059.
58. Schenker JG & Weinstein D. Clinical aspects of ovarian hyperstimulation syndrome: A current survey. Fertility and Sterility 1978; 30: 255-268.
59. Schenker JG. Prevention and treatment of ovarian hyperstimulation syndrome. Human Reproduction 1993; 8: 653-659.
60. Aboulghar MA, Mansour RT, Serour GI et al. Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstetrics and Gynaecology 1993; 81: 108-111.
61. Delbaere A, Bergmann PJM, Gervy-Decoster C et al. Angiotensin 2 immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: Implications for pathophysiology and clinical management. Fertility and Sterility 1994; 62: 731-737.
62. Fluker MR, Copeland YE & Yuzpe AA. An ounce of prevention: Outpatient management of the ovarian hyperstimulation syndrome. Fertility and Sterility 2000; 73: 821-824.
63. Hurwitz A, Aikenhead M, Caldwell C et al. Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy. Hypertension 2000; 36: 965-969.
64. Iwabe T, Harada T, Miura H et al. Laparoscopic unwinding of adnexal torsion caused by ovarian hyperstimulation. Human Reproduction 1994; 9: 2350-2352.
65. Pryor RA, Wiczyk HP & Oshea DL. Adnexal infarction after conservative surgical management of torsion of a hyperstimulated ovary. Fertility and Sterility 1995; 63: 1344-1346.